Why your Microbiome Matters
Your gut is home to more than 100 trillion microorganisms such as bacteria, fungi and microbes, collectively known as your gut microbiome. It’s the beautiful, hidden power that shapes your energy, mood, and immunity.
"When you protect it, it protects you."
What a Healthy Gut Looks like
A healthy microbiome is a diverse, balanced, and stable ecosystem of trillions of microorganisms in your gut. Its primary function is to guard your gut barrier.
Diverse
means many microbial species working together
Balanced
beneficial microbes keep pathogens in check
Stable
Strong enough to withstand daily challenges from stress, diet, and travel.
The Proven Benefits of Balance
- Over 70% of your immune cells live in your gut.
- Over 90% of your body’s serotonin, and
- Over 50% of dopamine is produced here.
Research shows a supported microbiota can help:
- Protect the gut lining and, therefore, immunity (Han et al., 2019)
- Build resilience against inflammation (Hojsak et al., 2010)
- Steady your energy, mood and focus (Sanborn et al., 2020; 2022)
- Improve digestion and, therefore, nutrient absorption (Jumpertz et al., 2011; Ouwehand et al., 2005)
Our mission: to bring you clinically proven strains, crafted with care, so you can feel clear, strong, and ready for life, whatever you’re doing, and wherever it takes you.
Meet the strains
Two world-leading probiotics. Clinically documented in over 500 human studies and 2,500 scientific publications worldwide - the most researched probiotic strains on earth.
Up to
+35%
Up to
+61%
Up to
-32%
Bifidobacterium animalis subsp. lactic, BB-12®
Clinically validated for digestive comfort and immune balance.
Up to
70%
Up to
50%
Up to
50%
Lacticaseibacillus rhamnosus, LLG®
The world's most documented probiotic strain - trusted for immune, gut, and barrier support.
Strain specific clinical studies
LGG Clinical Studies
| No. | Benefit Area | Strain | Population | Study-based Claim (Consumer language) | Study Type | Number of Participants | Duration | Mechanism of Action | Short Reference | Reference (PubMed link) | Study-based Claim (Scientific language) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Digestive health (infections) | LGG® | Daycare children | Helps reduce colds and tummy upsets in kids at daycare. | RCT | 571 | 7 months | ↑ mucosal IgA; barrier support; immune modulation (hypothesis) | Hatakka et al., 2001 | PMID: 11387176 | Reduced incidence of GI and respiratory infections and fewer antibiotic courses in daycare children. |
| 2 | Dermatological health (eczema prevention) | LGG® | High-risk infants | Supports healthy skin by lowering the risk of eczema in babies. | RCT + follow-up | 159 | Maternal last 4 wks pregnancy + 6 mo infant; follow-up 4 y | Early immune training; Th1/Th2 balance; ↑ Tregs; ↓ pro-inflammatory cytokines (hypothesis) | Kalliomäki et al., 2001/2003 | PMID: 11297958 / PMID: 12788576 | Perinatal LGG reduced incidence of atopic eczema in high-risk infants; preventive effect persisted to 4 y. |
| 3 | Immune health (URTIs) | LGG® | Daycare children | Helps reduce common colds in kids. | RCT | 281 | 3 months | ↑ mucosal IgA; antiviral pathways (hypothesis) | Hojsak et al., 2010 | PMID: 19896252 | Lower risk of URTIs vs placebo; LGG recommended in daycare (RCT). |
| 4 | Gut barrier function | LGG® | Human enteroids/colonoids (ex vivo) | Supports a healthy gut lining. | Translational model | N/A | Short-term assays (hours-days) | Secreted factors; TJ protein preservation; anti-inflammatory signaling | Han et al., 2019 | PMID: 30040527 | LGG prevented IFN-γ-induced tight-junction disruption and permeability increases in human enteroids/colonoids. |
| 5 | Gut-brain axis (cognition) | LGG® | Middle-aged & older adults | May support aspects of cognitive performance in older adults. | RCT | 68 (2020); 113 (2022) | 12 weeks | Microbiota-tryptophan/indole signaling; ↓ inflammation (hypothesis) | Sanborn et al., 2020/22 | PMID: 33223831 / PMID: 35617704 | LGG improved cognition in at-risk adults (2020), but follow-up trial in active adults was neutral. |
| 6 | Gut-brain axis (neurodevelopment) | LGG® | Infants → adolescence | Early LGG linked to fewer ADHD/Asperger cases. | RCT follow-up | 75 (subset of 159) | 6 mo intervention + 13 y follow-up | Early microbial-immune-neurodevelopment programming (hypothesis) | Pärtty et al., 2015 | PMID: 25760553 | At 13 y, ADHD/AS diagnoses 17% placebo vs 0% LGG group (pilot follow-up). |
| 7 | Micronutrient synthesis (Trp→B3) | LGG® | Preclinical + ex vivo | Emerging science: LGG may help generate vitamin-B3 metabolites. | Mechanistic | N/A | 2–8 wks (animal); hrs–days (cell) | Trp → nicotinamide/methyl-nicotinamide; TJ protection | Suntornsaratoon et al., 2024 | PMID: 38641207 | LGG + dietary tryptophan stimulated methyl-nicotinamide; protected against colitis (models). |
BB-12 Clinical Studies
| No | Benefit Area | Strain | Population | Study-based Claim (Consumer language) | Study Type | Number of Participants | Duration | Mechanism of Action | Short Reference | Reference (PubMed link) | Study-based Claim (Scientific language) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | Digestive health (regularity) | BB-12® | Adults w/ low stool frequency | Helps improve regularity and ease of bowel movements. | RCT | 124 | 4 weeks | ↑ Bifidobacterium; ↑ stool bulk | Eskesen et al., 2015 | PMID: 25240034 | BB-12 increased defecation frequency vs placebo in adults with low stool frequency. |
| 9 | Immune health (vaccine response) | BB-12® | Healthy adults | Supports the body’s defenses by enhancing vaccine response. | RCT | 211 | 6 weeks (2 before + 4 after vaccine) | ↑ dendritic/B-cell activity; ↑ IgA & IgG | Rizzardini et al., 2012 | PMID: 21899798 | BB-12 increased systemic and mucosal antibody responses to influenza vaccination. |
| 10 | Immune health (RTIs) | BB-12® | Infants | Helps reduce respiratory infections in babies. | RCT | 662 | 24 months (1 mo → 2 y) | ↑ mucosal sIgA; innate tone (hypothesis) | Taipale et al., 2016 | PMID: 26372517 | Infants receiving BB-12 had fewer RTIs vs controls (RR 0.87; P=0.033). |
| 11 | Anti-inflammatory effects (matrix-dependent) | BB-12® | Healthy adults | Can help calm inflammatory signaling; effect depends on product format. | RCT crossover | 36 | 4 wks per intervention + washout | ↓ TLR-2; ↓ TNF-α secretion | Meng et al., 2017 | PMID: 26621631 | BB-12 in yogurt smoothie lowered PBMC TNF-α secretion & TLR-2 expression. |
| 12 | Gut microbial balance | BB-12® | Healthy adults | Helps increase beneficial bifidobacteria in the gut. | RCT crossover | 36 | 4 wks per arm | Colonization; competitive exclusion | Ba et al., 2021 | ASM mSphere | BB-12 in yogurt smoothie ↑ B. animalis abundance in feces; overall microbiota stable. |
Your questions, answered.
Because clinically proven should also be clear-cut.
Are the Gutcultured bacteria strains clinically researched?
Yes. Both strains have extensive peer-reviewed clinical research and documentation, covering digestive health, immune support, infant health, antibiotic-associated outcomes and overall microbiome function.
Do our strains survive stomach acid and bile?
Yes. BB-12® and LGG® are documented for surviving harsh upper digestive conditions and effectively reaching the intestines alive.
How many CFUs does Gutcultured contain?
Each Gutcultured daily dose contains a clinically validated daily dose of 10 billion CFU, guaranteed. We focus on documented effectiveness, not inflated CFU counts that don’t correlate with real-world benefits.
Are the bacteria strains safe?
Yes. Safety profiles for BB-12® and LGG® are excellent and supported across diverse populations, women who are pregnant and breastfeeding, children from age 3 and long-term use. We still recommend discussing any new supplement with your healthcare provider.
Are there published studies I can read?
Yes. BB-12® and LGG® have hundreds of peer-reviewed studies, including placebo-controlled trials. We reference key publications on this page for transparency.